Abstract 5323
Background
In terminal cancer patients with a limited prognosis, excessive radiotherapy (RT) fractionation can be considered an avoidable harm and poor use of healthcare resource. 30-day mortality (30DM) as a clinical indicator for the avoidance of harm, through appropriate patient selection, in palliative RT has not previously been demonstrated in Hong Kong. We aimed to assess 30DM following palliative RT at our centre.
Methods
A retrospective analysis of 30DM for all palliative RT delivered in Tuen Mun Hospital in 2017. Episodes were identified using the in-house radiotherapy electronic record with linkage to electronic patient records. 30DM was assessed across all patient groups and by sites and fractionation pattern.
Results
1,065 palliative RT episodes were identified. Overall, 199 (18.7%) treatment were delivered to the spine, 151 (14.2%) to the chest, 97 (9.1%) to the brain, and 77 (7.2%) to the bones. Median treatment duration was 5 days (range 1–12). 84.3% received 5 fractions or less. Overall 30DM was 17.7% (188 patients), among which 61 (32.4%) treatment episodes were delivered to female. The most commonly treated diagnosis was lung cancer (39.4%). Factors having a significant impact upon 30DM were sex (male vs female odds ratio [OR] 1.56, 95% confidence interval [CI] 1.12, 2.18) and primary cancer diagnosis (Lip, oral cavity, and pharynx OR 0.31 [0.11, 0.87], genitourinary organs OR 0.57 [0.33, 0.98], and respiratory and intrathoracic organs 1.60 [1.17, 2.20]).Table:
1602P odd ratios for different factors relating to the 30DM of palliative RT
Yes (mortality within 30 days) | No | ||
---|---|---|---|
Total n = 1065 | No. of Cases (%) | No. of Cases (%) | Odd ratios (95% CI) |
Radiotherapy Sites | |||
Lip, oral cavity, and pharynx | 4 (7) | 57 (93) | 0.31 (0.11, 0.87) |
Genitourinary organs | 16 (11) | 124 (89) | 0.57 (0.33, 0.98) |
Bone, connective tissue, skin and breast | 23 (14) | 144 (86) | 0.71 (0.44, 1.14) |
Other and unspecified sites | 8 (17) | 40 (83) | 0.93 (0.43, 2.02) |
Digestive organs and peritoneum | 35 (18) | 159 (82) | 1.03 (0.69, 1.55) |
Respiratory and intrathoracic organs | 92 (22) | 328 (78) | 1.60 (1.17, 2.20) |
Lymphatic and hematopoietic Tissue | 10 (29) | 25 (71) | 1.92 (0.90, 4.06) |
Sex | |||
Male | 127 (20) | 501 (80) | 1.56 (1.12, 2.18) |
Female | 61 (14) | 376 (86) |
Abbreviation: CI: confidence interval
Conclusions
This is the first large-scale study of 30-day mortality for unselected adult palliative RT in Hong Kong. A balance needs to be achieved between duration of RT course and potential benefits through appropriate patient selection. The observed differences in early mortality by fractionation support the use of this measure in assessing clinical decision making in palliative RT, and further studies in other centres and health care systems are required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Shing Fung Lee.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
681 - Significance of the red blood cell distribution width in resected pathological stage I non-small cell lung cancer
Presenter: Gouji Toyokawa
Session: Poster Display session 1
Resources:
Abstract
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract